Abstract: Gliomas are the most common primary neoplasms of the central nervous system. Currently, surgery combined with radiotherapy and chemotherapy is the most popular treatment, but the effect is not ideal. In recent years, immunotherapy, particularly the passive immunotherapy, has shown promise, with its unique advantages in the adjuvant treatment of gliomas. This article reviews the usage and direction of recent developments in these aspects based on domestic and foreign studies.